SUMMARY
patients who had received a muscle relaxant had evidence of incomplete reversal of the neuromuscular blockade on arrival in the recovery room. Subsequent studies in Sweden 3 and Australia 4 have supported this important finding. The most serious consequence of residual curarisation is postoperative respiratory failure. A marked increase in the incidence of this potentially lethal complication was noted soon after the introduction of muscle relaxants into clinical practice. 5 Even now postoperative respiratory failure is still an important cause of anaesthetic mortality. 6, 7 In one recent European study 19070 of anaesthetic deaths were attributed to postoperative respiratory failure from residual curarisation. 6 The findings of Viby-Mogensen 2 may be explained by the observation that most attempts to antagonise a competitive neuromuscular blockade occur when there is greater than 90070 depression of twitch height compared with a preoperative control. 8 Complete antagonism of this degree of neuromuscular blockade with an anticholinesterase may take 30 minutes or longer. 9.10 Rapid and reliable antagonism of a competitive neuromuscular blockade will only occur if the neuromuscular blockade has spontaneously recovered to a sufficient degree by the time of reversal. If neuromuscular blockade is not monitored, reversal of the residual neuromuscular blockade is dependent upon the ability of the anaesthetist to predict the magnitude of the neuromuscular blockade at the end of the procedure. In clinical practice the response to competitive neuromuscular blocking agents has been found to be highly variable. This is illustrated by the findings of Katz," in which the administration of d-tubocurarine, 0.11 mg/kg, caused no neuromuscular blockade in 6070 of patients and 100% depression of control twitch heights in 7 %. The factors which cause this variability in response can be analysed in terms of the pharmacodynamics and pharmacokinetics of these agents. Pancuronium is the drug most extensively investigated in this respect, but there is strong evidence that its pharmacodynamic and pharmacokinetic properties in man are representative of all the longer-acting competitive neuromuscular blocking agents. [12] [13] [14] [15] There is a sigmoid-shaped relationship between the steady state plasma pancuronium concentration, or more precisely the concentration at its site of action (the biophase), and the degree of neuromuscular blockade (effect). A plot of the log effect/(l-effect) against log concentration is linear over a very wide range and is known as a Hill plot. A Hill plot can be characterised by the mean effective concentration for 50% depression of control twitch heigqt (ECp50) and the gradient of the linear portion of the curve. 16 A Hill plot for a patient who has received pancuronium is illustrated in Figure 1 . Table 1 summarises these pharmacodynamic characteristics of pancuronium as determined in studies in which similar stimulus and measurement conditions were applied. Extrapolation from these results suggests that the clinically effective concentration of pancuronium, the ECp90, is highly variable. When the variable potentiating effects of volatile anaesthetic agents are also considered,19.22 it becomes impossible in an individual patient to accurately predict the ECp90 of pancuronium during anaesthesia. The pharmacokinetic properties of pancuronium as determined in normal patients are summarised in Table 2 . The mean values for the different pharmacokinetic parameters are similar, with the minor differences between the studies being attributed to differences in experimental design and/or analytical technique. 14 An important feature of these results is the large degree of variation found for each of the pharmacokinetic parameters. An illustration of the possible clinical effect of this variation is reproduced from the work of Norman 27 in Figure 2 . Using the pharmacokinetic data of Shanks,23 it shows the simulated plasma time course of a 100 J,lg/kg bolus dose of pancuronium. The plasma pancuronium concentration for adequate neuromuscular blockade (the effective concentration for 90070 twitch depression) has been taken to be 200 J,lg/ml for the anaesthetic technique employed. In the average patient the neuromuscular blockade will remain adequate for 59 minutes and thereafter be readily reversible. However, should the four basic pharmacokinetic parameters each vary by one standard deviation from the mean, the fastest decline from a plasma pancuronium concentration of 200 J,lg/ml will occur in approximately 29 minutes and the slowest in 116 minutes. This range should cover 99070 of the population, but in an individual patient one cannot predict the duration of the neuromuscular blockade.
METHODS OF ADMINISTRATION OF MUSCLE RELAXANTS
The pharmacodynamic and pharmacokinetic variability of competitive neuromuscular blocking agents makes it impossible to accurately predict in an individual patient the magnitude of the neuromuscular blockade at the completion of surgery when simple criteria such as the dose of muscle relaxant, the duration of the procedure and a patient parameter such as body mass are used. The only practical approach to the use of these agents is to titrate the drug administration against effect by monitoring neuromuscular function. 28 ,29 If large supplementary doses are administered, an accurate estimation of both the duration of the procedure and the dose of muscle relaxant is required if the neuromuscular blockade is to be reversible on completion of the procedure. Unfortunately it is difficult to accurately predict either. The administration of small doses allows more precise control of muscle relaxation during surgery but frequent administration is inconvenient and can be a distraction for the anaesthetist. In the extreme case, the frequent injection of small doses is equivalent to a continuous infusion.
The efficacy of administering competitive neuromuscular blocking agents, particularly atracurium and vecuronium, by continuous infusion has been confirmed in clinical studies. 30 -32 The continuous infusion of a muscle relaxant provides a flexible and accurate method for maintaining a precise degree of muscle relaxation during surgery. The advantages of the technique are most pronounced when the shorter-acting competitive neuromuscular blocking agents are administered. The infusion rate necessary to maintain a stable neuromuscular blockade quickly becomes constant because of the short duration of action and lack of cumulative effects of these agents. The prompt spontaneous recovery which ensues when the infusion is discontinued or the rate changed means that the degree of neuromuscular blockade can be readily varied with changing surgical requirements and can remain optimal till the end of the procedure while still ensuring rapid reliable reversibility. 30,31
The shorter-acting competitive neuromuscular blocking agents may be inherently safer to use than the longer-acting agents. A preliminary study has shown that the intermittent administration of atracurium is associated with better recovery and a lower incidence of residual curarisation when compared with pancuronil!lm. 33 Intermittent bolus administration of the short-acting competitive neuromuscular blocking agents during prolonged surgery, apart from being inconvenient, tends to cause wide fluctuations in the level of the neuromuscular blockade intraoperatively even when it is closely monitored. 34 ,35 These agents are therefore not suited for use during prolonged surgery unless administered by continuous infusion.
The short-acting competitive neuromuscular blocking agent most suited to administration by infusion is atracurium, In comparison with vecuronium, atracurium has less tendency to accumulate,36 and, most importantly, a shorter recovery time after the infusion is ceased. 3o ,31 These pharmacokinetic properties are also relatively independent of patient condition, as its rapid inactivation by Hofmann elimination and ester hydrolysis is not dependent on hepatic or renal function. 37 CONTINUOUS iNFUSION OF A TRACURIUM The infusion rates necessary to maintain a stable level of neuromuscular blockade during a continuous infusion of a competitive neuromuscular blocking agent are highly variable and some form of monitoring of neuromuscular function is required. 30-32 Sophisticated automated feedback controlled infusion systems for muscle relaxants have been developed 38 ,39 but comparable results can be obtained with manual assessment of the degree of neuromuscular blockade and adjustment of the infusion rate.
In this method, the neuromuscular blockade is monitored by tactile assessment of thumb adduction using a modified train-of-four count following supramaximal stimulation of the ulnar nerve. The basis and requirements of clinical monitoring using this technique have been dealt with extensively in recent review articles. 28 ,29 A prerequisite for the technique is the availability of a suitable peripheral nerve stimulator. The peripheral nerve stimulator must have a maximum output of at least 60 mA to ensure supramaximal stimulation when surface gel electrodes are used,4o On the other hand the stimulation current must not be too high as direct muscle stimulation may occur which can interfere with the assessment of the neuromuscular blockade. 29 Therefore the current required for supramaximal stimulation should be determined before the administration of any muscle relaxant. This can be achieved by either of two techniques. While assessing the force of thumb adduction in response to repetitive single stimuli at 1.0 Hz, a supramaximal stimulus is being delivered when the output of the stimulator no longer causes a rapid increase in the force of thumb adduction. Thereafter the force of thumb adduction continues to increase slowly and reaches a maximum with the maximum output of the stimulator. 40 An alternative method for determining the supramaximal stimulus can be used if the peripheral nerve stimulator has a digital ammeter. At a stimulus rate of 1.0 Hz the initial threshold for stimulation, the current required for the first clearly visible twitch of the thumb, is noted. Then, provided a minimum of 20 mA is delivered to achieve supramaximal stimulation, supramaximal stimulation can be assured if the delivered current is three times that required for the initial threshold for stimulation,4o
Atracurium may be delivered by a variable rate infusion device such as a syringe pump, For a 50 ml syringe, the pump should have an adjustable rate between 0 and 100 mllhr. The concentration of the infused atracurium is varied, based on the weight of the patient (atracurium concentration mg/ml = kg body weight/WO). The atracurium is diluted in 0.9070 w/v saline in which it is relatively stable, with no significant decomposition of the atracurium occurring in such a solution over a period of four hours at ambient temperature (25 QC). 10 Muscle relaxation is initially obtained with either a bolus dose of atracurium, 0.6 mg/kg, or with suxamethonium followed by a smaller bolus dose of atracurium, 0.3 mg/kg. The neuromuscular blockade is subsequently monitored every five minutes by a modified train-of-four count, with the infusion commenced at 30 mllhr (0.005 mg/kg/min) when the first detectable response to stimulation returns. Thereafter the infusion rate is adjusted to maintain one obvious response to train-of-four stimulation with the initial adjustments in the infusion rate being in increments of 10 mllhr. It must be remembered that there is approximately a five-minute lag between an adjustment of the infusion rate and a change in the neuromuscular blockade. If necessary a small bolus dose of atracurium may be administered. The steady state infusion rate is usually obtained within 15-20 minutes. The infusion is ceased when muscle relaxation is no longer required. Complete recovery is confirmed by a sustained response to a 50 Hz tetanus stimulation.
CLINICAL STUDY
The efficacy of this technique has been determined in a study which was approved by the Medical Ethics Committee of the hospital. To 20 patients, who gave informed consent, an infusion of atracurium was administered and managed according to the method outlined above with the anaesthetist monitoring neuromuscular blockade by tactile estimation of thumb adduction in response to ulnar nerve stimulation. The neuromuscular blockade was measured and recorded in the opposite arm using a force transducer by recording the response of adductor pollicis to supramaximal stimulation of the ulnar nerve but the findings were not revealed to the responsible anaesthetist. A typical recording is illustrated in Figure 3 . In all cases the neuromuscular blockade was maintained at greater than 80070 depression of control twitch height during the infusion, the mean minimum neuromuscular blockade during this time being 86070 (SD 6) depression of control twitch height. The maintenance infusion rate was 0.006 (SD 0.002) mg/kg/min. The residual neuromuscular blockade was rapidly reversed with neostigmine, mean reversal time (time from administration of neostigmine to 95070 postrecovery twitch height) of 5 (SD 2) minutes.
The technique has since been used in a further 50 patients and has been found to be a simple and reliable method of providing neuromuscular blockade during prolonged surgical procedures. Individual cases highlighted some of the advantages of the infusion technique, particularly those involving unexpected changes in the duration of the procedure or in the requirements for muscle paralysis during the procedure. No patient had any evidence of residual curarisation when tested on arrival in the recovery room. The responsible anaesthetist was unaware of this recording and managed the muscle paralysis during the surgery according to the method described in the text. An initial bolus dose of 0.6 mg/kg atracurium was administered, with the infusion of atracurium commenced 40 min later at 30 ml/hr. The neuromuscular blockade was maintained at 95070 depression of control twitch height throughout the duration of the infusion. The infusion was ceased after 101 min and the patient was reversed 8 min later when the train-of-four count was 2, with neostigmine 3.8 mg and atropine 1.8 mg.
blockade is one means by which the safety with which these agents are administered can be improved. A variable rate continuous infusion of short-acting competitive neuromuscular blocking agents with monitoring of the neuromuscular blockade is the most flexible and accurate method of maintaining a precise degree of neuromuscular blockade during prolonged surgery. The technique ensures reliable reversibility of the residual neuromuscular blockade at the end of the procedure by avoiding excessive degrees of neuromuscular blockade which may occur following intermittent boluses. The increased cost and complexity of administration of these agents by infusion is believed to be more than offset by the advantages.
